Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;42(1):32-5.
doi: 10.4103/0253-7613.62409.

Effective control of sickle cell disease with hydroxyurea therapy

Harminder Singh  1 , Navin Dulhani, Bithika Nel Kumar, Prabhakar Singh, Pawan Tiwari
Affiliations

Effective control of sickle cell disease with hydroxyurea therapy

Harminder Singh et al. Indian J Pharmacol. 2010 Feb.

Abstract

Objective: Hemoglobin F augmentation is another approach to treat sickle cell disease (SCD). This study evaluates the efficacy and impact of Hydroxyurea (HU) on fetal hemoglobin (HbF) and other hematological parameters, which result in decreasing the painful crisis and lower hospital admissions.

Materials and methods: A prospective study was carried out in the Department of Medicine, Government Medical College, Jagdalpur. Twenty-seven patients with SCD received HU at a mean dose of 22 mg/kg/d. The baseline results were analyzed and compared with the post treatment result, at the end of one year.

Statistics: Student's t-test was used to determine the level of significance.

Results: Twenty-four patients completed a one-year period successfully; a significant increase was noted in the mean HbF%, from 12.83 to 19.17, and the mean corpuscular volume (MCV) from 82.57 to 89.87 Fl. The mean hospital admission (numbers) in the last one year decreased from 4.75 to 2.25 and the mean number of SCD crisis for the last one year decreased significantly from 3.63 to 1.67.

Conclusion: We found a significant reduction in hospital admissions, a reduction in the overall sickle cell crisis and an associated improvement in HbF% without any significant side effects in the patients with SCD, treated with HU.

Keywords: Fetal hemoglobin; Hydroxyurea; Sickle cell anemia; Sickle cell disease.

PubMed Disclaimer

References

    1. Williams VL. Pathways of innovation: A history of the first effective treatment for sickle cell anemia. Perspect Biol Med. 2004;47:552–63. - PubMed
    1. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: The European experience. Am J Pediatr Hematol Oncol. 1994;16:18–21. - PubMed
    1. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317–22. - PubMed
    1. Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment. Hematology Am Soc Hematol Educ Program. 2000:2–17. - PubMed
    1. Bunn HF. Induction of fetal hemoglobin in sickle cell disease. Blood. 1999;93:1787–9. - PubMed